Most Popular - Intercept Pharmaceuticals’ (ICPT) shares immediately took off from their late October IPO price of $15 per share, soaring to a closing high of $41.70 on … Continue Reading
Read NowLong Ideas - Since our last report on Achillion Pharmaceuticals (ACHN) in November, shares have turned up a muted performance, losing around 7%. Through February, shares rose steadily, … Continue Reading
Read NowMost Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read NowLong Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read NowMost Popular - PropThink kicked off the week by revisiting Endo Health (ENDP) and brought the scoop on Rajiv De Silva’s materializing plans for the company. De Silva, … Continue Reading
Read NowLong Ideas - Since our report on Alexion Pharmaceuticals (ALXN) in early December, shares are virtually flat; outperformance through mid-January has been replaced by underperformance as expectations of … Continue Reading
Read NowLong Ideas - As we wrote last week, Endo Health’s (ENDP) newly appointed CEO and former Valeant (VRX) operating star Rajiv De Silva is on the road with … Continue Reading
Read Now